Influence of Intermittent Hypoxia on Loop Gain in Healthy Subjects

Sleep apnea (formally SAHOS) affects millions worldwide and is strongly linked to cardiovascular disease, yet the biological reasons why some people develop unstable breathing patterns during sleep remain poorly understood. A key concept here is 'loop gain' (LG) — a measure of how sensitively and strongly the respiratory control system responds to a drop in oxygen or rise in CO₂. High loop gain means the system overreacts, creating oscillating cycles of apnea and arousal. This trial, registered at Poitiers University Hospital and planned to begin recruiting in May 2026, asks a fundamental chicken-and-egg question: do some people simply have an inherently high loop gain that predisposes them to apnea, or does the intermittent hypoxia caused by repeated apneas itself train the system toward higher loop gain over time? The study will expose healthy volunteers to controlled intermittent hypoxia and measure whether their loop gain changes as a result. It will also investigate a parallel vascular pathway: intermittent hypoxia increases reactive oxygen species (ROS), which cause oxidative stress, endothelial dysfunction, and may involve extracellular vesicles as signaling intermediaries. By using healthy subjects with no pre-existing apnea, the design isolates the causal effect of hypoxia itself, free from confounders present in patient populations. If intermittent hypoxia does raise loop gain in otherwise normal individuals, this would reframe OSA as partly a self-perpetuating disorder and open new phenotype-targeted treatment strategies.

• Study not yet recruiting (planned start May 2026) — no efficacy or outcome data are available at this stage; all findings below are protocol-level objectives, not results.
• Primary mechanistic question: whether controlled intermittent hypoxia exposure in healthy subjects causally increases loop gain, independent of any pre-existing respiratory control phenotype.
• Secondary mechanistic question: whether intermittent hypoxia-induced ROS production and extracellular vesicle signaling mediate the vascular endothelial dysfunction observed in OSA, potentially linking ventilatory instability to cardiovascular comorbidity.

This is a prospective interventional study in healthy adult volunteers with no diagnosed sleep-disordered breathing, registered by Poitiers University Hospital (NCT07409649). Participants will undergo a controlled intermittent hypoxia protocol designed to mimic the oxygen desaturation profile of obstructive sleep apnea. Loop gain will be quantified before and after the hypoxic exposure using established respiratory physiology techniques; vascular and oxidative-stress biomarkers (including ROS levels and extracellular vesicles) will also be assessed. Full sample size, precise hypoxia protocol parameters, and follow-up duration are not yet disclosed in the public registration.

Because the study has not yet begun recruiting, no empirical findings exist and all conclusions here are speculative extrapolations from the protocol rationale — confidence in any specific outcome claim is low. The use of healthy volunteers strengthens internal validity for causal inference but limits direct generalizability to OSA patients, who may have additional confounders such as obesity, age-related vascular changes, or pre-existing autonomic dysfunction. The study cannot, by design, determine whether long-term clinical OSA amplifies loop gain beyond what acute experimental hypoxia produces. The next logical experiment would apply the same hypoxia paradigm to newly diagnosed, untreated OSA patients and compare LG trajectories before and after CPAP-mediated normoxia restoration.

This trial extends [§109], which characterizes OSA-related systemic inflammation via METTL14/JAK2/STAT3 macrophage polarization, by probing the upstream hypoxic trigger — intermittent oxygen desaturation — that may initiate such inflammatory cascades; together they map OSA pathophysiology from causal stimulus to downstream immune effector. It parallels [§95] (OSADA trial), which examines OSA as a mechanistic driver of airway hyperreactivity, in that both studies treat OSA-associated intermittent hypoxia as an active pathophysiologic agent rather than a passive symptom. The vascular oxidative-stress arm of this study also contextualizes [§96], which documents neurocognitive and cardiorespiratory comorbidities in elderly OSA patients with COPD, by offering a potential mechanistic explanation — endothelial dysfunction driven by ROS — for the systemic burden those patients carry. Because loop gain is a quantitative physiological phenotype, findings here could ultimately inform precision-medicine stratification efforts relevant to [§47], where OSA severity is linked to glymphatic pathway alterations, suggesting that ventilatory control instability may have neurovascular consequences beyond the lung.

• METTL14 Regulates Adipose Tissue Macrophage Polarization via JAK2 / STAT3 Pathway to Attenuate Obstructive Sleep Apnea‐Related Systemic Inflammation
  Directly complementary OSA mechanistic study: where this trial targets the hypoxic induction of loop gain and vascular ROS, [id=109] characterizes the downstream macrophage-mediated inflammatory response — together they span cause and consequence in OSA pathobiology.
• Obstructive Sleep Apnoea and Difficult Asthma (OSADA)
  Both treat intermittent hypoxia as an active pathophysiologic driver rather than a side-effect; [id=95] examines airway hyperreactivity as the end-organ outcome, providing a useful parallel for how OSA-related hypoxia remodels physiological control loops in different systems.
• Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
  Larger, patient-based cohort study of OSA comorbidities (neurocognitive decline, COPD interaction) that complements this mechanistic healthy-volunteer trial — readers can compare the bench-level causal question here against real-world multimorbidity outcomes there.
• Association between obstructive sleep apnea severity and glymphatic-related DTI-ALPS alterations in newly diagnosed, Drug-Naïve Alzheimer's disease
  Links OSA severity to glymphatic dysfunction via DTI-ALPS imaging, raising the question of whether high-loop-gain phenotypes (the focus of this trial) carry disproportionate neurovascular risk — a hypothesis this protocol cannot test but that [id=47] data could inform.
• Effects of chronic jetlag on high-fat and high-fructose diet induced renal injury in mice
  Examines a different chronic intermittent physiological stressor (circadian disruption via jet-lag) and its organ-level consequences, offering a useful conceptual comparison for how episodic physiological perturbations — hypoxic or circadian — can durably remodel homeostatic control systems.